Drug
Dovitinib clinical trials
Also written TKI258 and TK1258.
Includes 4 studies of Dovitinib lactate hydrate.
- studies test it
- 57
- open now
- 0
- in phase 3
- 1
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
55 studies that test it; most in 2012 (18)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 9 |
| 2012 | 18 |
| 2013 | 11 |
| 2014 | 2 |
| 2015 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 25
- Phase 2
- 34
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 33
Novartis Pharmaceuticals (22) · Asan Medical Center (4) · M.D. Anderson Cancer Center (4) · Roswell Park Cancer Institute (2) · Ontario Clinical Oncology Group (OCOG) (2) · Georgetown University (2) · Korean Cancer Study Group (1) · Abramson Cancer Center at Penn Medicine (1)
Often tested with
Tested in the same studies.
Gemcitabine (2) · Capecitabine (2) · Paclitaxel (2) · Fluvoxamine (1) · Caffeine (1) · Diclofenac (1) · Omeprazole (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses dovitinib is read from its arms, and is right about nine times in ten.
Testing it · 57
- Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsTerminatedPhase 1Allarity TherapeuticsNCT05571969Written as 2X-121 + 300 mg dovitinib
- Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary CancersCompletedPhase 1Roswell Park Cancer InstituteNCT01497392Written as dovitinib lactate
- Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expressionTerminatedPhase 2Noah Hahn, M.D.NCT01732107Written as Dovitinib
- Safety of TKI258 in Advanced/Metastatic Melanoma SubjectsCompletedPhase 1/2Novartis PharmaceuticalsNCT00303251Written as TKI258
- Dovitinib(TKI258) in Patients With Castration-resistant Prostate CancerCompletedPhase 2Korean Cancer Study GroupNCT01741116Written as TKI258
- A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell CancerCompletedPhase 1Novartis PharmaceuticalsNCT00715182Written as TKI258
- Phase I Dose Escalating Study of TKI258CompletedPhase 1Novartis PharmaceuticalsNCT01471548Written as TKI258
- Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01030055Written as TKI258 (dovitinib)
- Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01421004Written as TKI258
- Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic FunctionCompletedPhase 1Novartis PharmaceuticalsNCT01443481Written as Dovitinib
- Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01155713Written as TKI258
- Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.CompletedPhase 1Novartis PharmaceuticalsNCT01700270Written as dovitinib (TKI258)
- Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01596647Written as TKI258
- Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid MalignanciesCompletedPhase 1Novartis PharmaceuticalsNCT00669097Written as TKI258
- Phase II Study of TKI258 in Advanced Urothelial CarcinomaCompletedPhase 2Novartis PharmaceuticalsNCT00790426Written as TKI258
- Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal TranslocationCompletedPhase 2Novartis PharmaceuticalsNCT01058434Written as TKI258
- Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast CancerCompletedPhase 2Novartis PharmaceuticalsNCT00958971Written as TKI258
- Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid TumorsTerminatedPhase 1Centro Nacional de Investigaciones Oncologicas CARLOS IIINCT01548924Written as Dovitinib
- Dovitinib in Neuroendocrine TumorsCompletedPhase 2Abramson Cancer Center at Penn MedicineNCT01635907Written as Dovitinib
- Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258CompletedPhase 2Asan Medical CenterNCT01440959Written as dovitinib
See all 57 studies that test dovitinib →
Given in every arm · 1 — dovitinib is usual care beside what is tested
Codes
What other systems call dovitinib · ClinicalTrials.gg INT004769
- UNII (FDA) I35H55G906DOVITINIBConfirmed FDA, Wikidata
- Wikidata Q27453625dovitinibConfirmed FDA, Wikidata
- NCI Thesaurus C76199DovitinibOne source FDA
- DrugBank DB05928One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | I35H55G906 | DOVITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27453625 | dovitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C76199 | Dovitinib | One source FDA |
| DrugBank | DB05928 | — | One source Wikidata |
Also registered as dovitinib lactate anhydrous (UNII B82T791274).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.